Author:
Zou Lingxiao,Li Waixing,Xu Dabao,Zhu Shujuan,Jiang Bin
Abstract
Abstract
Objective
To explore the N6-methyladenosine (m6A) methylation abnormality of mRNAs and its potential roles in the mouse model of polycystic ovary syndrome (PCOS).
Methods
The mouse model of PCOS were induced by injecting dehydroepiandrosterone (DHEA), and confirmed by observing the morphological structures of ovarian follicles. Subsequently, m6A-tagged mRNAs were identified via m6A epitranscriptomic microarray and its potential functional pathways were predicted in KEGG database. The expression and modification levels of key mRNAs in the most enriched pathway were evaluated and compared using western blot and methylated RNA immunoprecipitation-quantitative PCR (MeRIP-qPCR).
Results
Compared with the control group, 415 hypermethylated and downregulated mRNAs, 8 hypomethylated and upregulated mRNAs, and 14 hypermethylated and upregulated mRNAs were identified in the PCOS group (Fold change ≥ 1.5). Those mRNAs were mainly involved in insulin signaling pathway, type II diabetes mellitus, Fc epsilon RI signaling pathway, inositol phosphate metabolism, and GnRH secretion. In insulin signaling pathway, the expression levels of phosphorylated protein kinase B (p-AKT) were decreased, whereas that of upstream phosphorylated phosphatidylinositol 3-kinase (p-PI3K) were increased in PCOS group. Moreover, skeletal muscle and kidney-enriched inositol polyphosphate 5-phosphatease (SKIP), one of PIP3 phosphatases, was verified to be overexpressed, and Skip mRNAs were hypermethylated in PCOS group.
Conclusion
The altered m6A modification of mRNAs might play a critical role in PCOS process. The PI3K/AKT pathway is inhibited in the mouse model of PCOS. Whether it is caused by the m6A modification of Skip mRNAs is worthy of further exploration.
Funder
the Young Scientists Fund of the Hunan Provincial Natural Science Foundation of China
the Changsha Natural Science Foundation
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Oncology
Reference45 articles.
1. Kostroun KE, Goldrick K, Mondshine JN, Robinson RD, Mankus E, Reddy S, et al. Impact of updated international diagnostic criteria for the diagnosis of polycystic ovary syndrome. F S Rep. 2023;4:173–8.
2. Livadas S, Paparodis R, Anagnostis P, Gambineri A, Bjekic-Macut J, Petrovic T, et al. Assessment of type 2 diabetes risk in young women with polycystic ovary syndrome. Diagnostics (Basel). 2023;13:2067.
3. Lo A, Lo C, Oliver-Williams C. Cardiovascular disease risk in women with hyperandrogenism, oligomenorrhea/menstrual irregularity or polycystic ovaries (components of polycystic ovary syndrome): a systematic review and meta-analysis. Eur Heart J Open. 2023;3: d61.
4. Allen LA, Shrikrishnapalasuriyar N, Rees DA. Long-term health outcomes in young women with polycystic ovary syndrome: A narrative review. Clin Endocrinol (Oxf). 2022;97:187–98.
5. Zaib S, Rana N, Khan I, Waris A, Ahmad U. Analyzing the challenges, consequences, and possible treatments for polycystic ovary syndrome. Mini Rev Med Chem 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献